Dare Bioscience (NASDAQ: DARE)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-11 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.140 | -0.100 | 0.0400 | ||||
REV | 360.000K | 0 | -360.000K |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of Dare Bioscience (NASDAQ: DARE) through any online brokerage.
Other companies in Dare Bioscience’s space includes: Opiant Pharma (NASDAQ:OPNT), Satsuma Pharmaceuticals (NASDAQ:STSA), Lipocine (NASDAQ:LPCN), Qilian Intl Hldg Gr (NASDAQ:QLI) and PLx Pharma (NASDAQ:PLXP).
The latest price target for Dare Bioscience (NASDAQ: DARE) was reported by HC Wainwright & Co. on Friday, April 1, 2022. The analyst firm set a price target for 6.00 expecting DARE to rise to within 12 months (a possible 380.00% upside). 1 analyst firms have reported ratings in the last year.
The stock price for Dare Bioscience (NASDAQ: DARE) is $1.25 last updated June 29, 2022, 8:00 PM UTC.
There are no upcoming dividends for Dare Bioscience.
Dare Bioscience’s Q2 earnings are confirmed for Thursday, August 11, 2022.
There is no upcoming split for Dare Bioscience.
Dare Bioscience is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.